NanoVibronix

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. It targets wound healing and pain therapy, and can be administered at home, without the assistance of medical professionals. The firm's products include WoundShield, PainShield, and UroShield. It operates through the following geographical segments: United States, Israel, Europe, India, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Elmsford, NY.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with Mio-Guard, LLC (“Mio-Guard”) for the sale and distribution of its PainShield MD product. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, "This new distribution agreement is a great o.

NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced that independent life expectancy testing performed by Carmel Labs in Israel confirm that its PainShield met all tested functionalities.

NanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS)

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Multiple Frequency Surface Acoustic Waves for Internal Medical Device” (the "Patent Application") related to its UroShield.

NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced the positive evaluation results for its UroShield device, presented at a recent medical conference by clinicians from the Royal National Orthopaedic Hospital (“RNOH”).

NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it intends to launch a month to month rental program on March 1, 2023 for its lead products, PainShield and UroShield.

NanoVibronix to Launch Rental Program for PainShield and UroShield

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Wednesday, February 8, 2023.

NanoVibronix Announces Reverse Stock Split

ELMSFORD, N.Y.--( BUSINESS WIRE )-- NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided an update on the efforts to expand access to the Company's PainShield product.

NanoVibronix Provides Update on Expanding Access to PainShield

ELMSFORD, N.Y.--( BUSINESS WIRE )--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the “Annual Meeting”) was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022.

NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

ELMSFORD, N.Y.--( BUSINESS WIRE )--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it has partnered with Peak Medical, Ltd., a continence care patient focused company based in the United Kingdom.

NanoVibronix Announces Partnership with Peak Medical, Ltd.

ELMSFORD, N.Y.--( BUSINESS WIRE )--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, of 4,800,000 shares of its common stock at a purchase price of $0.50 per share.

NanoVibronix Announces Closing of $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NanoVibronix (NASDAQ: NAOV ) stock is falling on Tuesday following news of a registered direct offering from the therapeutic ultrasound technology company. This direct offering has NanoVirbronix agreeing to sell 4.8 million shares of NAOV stock to several institutional investors.

What Is Going on With NanoVibronix (NAOV) Stock Today?

ELMSFORD, N.Y.--( BUSINESS WIRE )--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it has entered into a securities purchase agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 4,800,000 shares of its common stock (or pre-funded warrants in lieu of thereof) at a purchase price of $0.50 per share (or pre-funded warrant in lieu thereof). The offering is expected to close on or about December 1, 2022, subject to satisfaction of customary closing conditions.

NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ELMSFORD, N.Y.--( BUSINESS WIRE )--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield® MD PLUS, its dual-actuator ultrasound pain therapy device.

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

ELMSFORD, N.Y.--( BUSINESS WIRE )-- NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced interim results of its U.K. clinical study for UroShield that is being conducted by The University of Southampton and the National Biofilms Innovation Centre.

NanoVibronix Announces Interim Results of Clinical Study for UroShield

ELMSFORD, N.Y.--( BUSINESS WIRE )-- NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided the following business update in a letter to shareholders from its Chief Executive Officer, Brian Murphy:

NanoVibronix Provides Business Update in Letter to Shareholders

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

Kiromic Biopharma

Sonendo

Use this guide for investing in penny stocks in the long term The post Long Term Penny Stocks Investing Strategy (Complete Guide) appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Long Term Penny Stocks Investing Strategy (Complete Guide)

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its UroShield has been approved for sale by the U.K.'s National Health System's (NHS) internal supply organization, NHS Supply Chain, through a new contract. Brian Murphy, CEO of NanoVibronix, stated, “This new contract with NHS Supply Chain provides dedicated end-to-end supply chain s

NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), announced today that its annual meeting of shareholders (the “Annual Meeting”) will take place at 10 a.m. Eastern time on December 15, 2022. The Company will hold the Annual Meeting virtually via the internet. The record date for determination of shareholders entitled to vote at the Annual Meeting is October 17, 2022. The Company anticipates sending proxy materials for the Annual Meeting to stockholders in Nove

NanoVibronix Sets Date for Annual Shareholder Meeting

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“Nano” or the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on Oc

NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that, based upon the Company's continued non-compliance with Nasdaq's minimum bid price requirement as of August 29, 2022, the Company securities would be subject

NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its Australian distributor, DukeHill HC, is launching a series of educational webinars to present the Company's UroShield technology to clinicians. The series, which will feature clinicians and patients' experiences, seeks to inform clinicians about the use, benefits and outcomes achie

NanoVibronix Announces Webinar Series to Promote UroShield

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it is shifting the majority of its manufacturing operations to Singapore in order to allow scalability increase efficiency and address potential supply chain delays. “Plans are well underway to shift the majority of our third-party manufacturing to the industrial hub of Singapore,” stat

NanoVibronix Strengthening Supply Chain Increasing Efficiency and Scalability

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to aba

NanoVibronix Reports First Quarter 2022 Financial Results

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its PainShield® MD PLUS, its dual-actuator ultrasound pain therapy device. Brian Murphy, CEO of NanoVibronix, stated, “This submission is an important step towards full commercialization

News for NanoVibronix Stock (NAOV)